echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Antibody | Looking at the research and development overview of the popular target Claudin 18.2 from the FDA approval of TJ-CD4B in Phase 1 clinical trials

    Antibody | Looking at the research and development overview of the popular target Claudin 18.2 from the FDA approval of TJ-CD4B in Phase 1 clinical trials

    • Last Update: 2021-04-19
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com



    TJ-CD4B is an innovative bispecific antibody that simultaneously targets the tumor antigen claudin 18 splicing body 2 (Claudin 18.


    Preclinical studies have shown that even in the case of low expression of Claudin 18.


    This time, approved in the United States is a multi-center Phase 1 dose-climbing trial, which will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of TJ-CD4B in patients with advanced or metastatic solid tumors.


    Claudins are a family of proteins whose role is to maintain tight junctions that control the exchange of molecules between cells.


    Claudin 18.


    Current status of Claudin 18.


    It is the highly selective expression of Claudin 18.




    SPX-301 is a bispecific antibody drug developed by Sparx that simultaneously targets claudin18.


    CLDN 18.




    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.